Multicentre prospective non-interventional study protocol for evaluating surgical strategies for Colorectal Resections and Postoperative Quality of Life in Retroperitoneal Sarcoma Patients Across German-Speaking Sarcoma Centres (COLOSARC-Q) Authors: Madelaine Hettler, Katrin R Scharpf, Anna Eich, Markus Albertsmeier, Anna Duprée, Svetlana Hetjens, Melissa Harbrücker, Franka Menge, Alexander Betzler, Peter Hohenberger, Jens Jakob Published: 2025 ABSTRACT AbstractIntroductionRetroperitoneal sarcomas (RPS) are rare and often large malignancies that frequently require extensive surgery for complete tumour removal. Resections of the colorectum are part of the standard resection, this way contributing to complication rates, including anastomotic leakage or obstruction. Surgical strategies for stoma formation and colorectal reconstruction remain poorly defined. The Colorectal Resections and Postoperative Quality of Life in Retroperitoneal Sarcoma Patients Across German-Speaking Sarcoma Centres (COLOSARC-Q) study aims to explore surgical procedures and health-related quality of life (HRQoL) in patients undergoing colorectal procedures during RPS surgery.Methods and analysisCOLOSARC-Q is a prospective, multicentre, non-interventional study and will recruit 120 patients with primary RPS who undergo colorectal resection as part of sarcoma surgery in a sarcoma referral centre in Germany or Switzerland. HRQoL is assessed using standardised questionnaires (EORTC QLQ-C30, QLQ-CR29) as well as semi-structured interviews by psycho-oncology services and patient advocates. Data will be collected via an electronic Case Report Form, encompassing demographic, clinical, surgical and outcome-related information. All data will be centrally analysed. For the assessment of quality of life, a qualitative analysis with content and context analysis, as well as evaluation of the questionnaires according to a standardised scoring system, is planned. The primary aim is to evaluate surgical techniques for bowel resection and reconstruction and their influence on the further course of disease. Secondary endpoints assess postoperative complications as well as tumour-, patient- and treatment-related factors.Ethics and disseminationEthical approval was granted by the Ethics Committee II of the University of Heidelberg (approval number 2024-562; 13 June 2024). The data protection review was approved by the data protection officer of the University of Heidelberg. Participation of other centres in the study requires local ethical approval. All patients will be required to sign an informed consent form. Results of primary and secondary endpoints will be published.Trial registration numbersNCT06943612; German Clinical Trials Registry (DRKS00034135). STRENGTHS AND LIMITATIONS OF THIS STUDY Multicentre design captures diverse surgical practices at certified sarcoma expert centres. Multicentre design captures diverse surgical practices at certified sarcoma expert centres. Combined prospective and retrospective data collection ensures comprehensive clinical and surgical information. Combined prospective and retrospective data collection ensures comprehensive clinical and surgical information. Use of standardised health-related quality of life questionnaires and semi-structured interviews provides detailed patient-reported outcomes. Use of standardised health-related quality of life questionnaires and semi-structured interviews provides detailed patient-reported outcomes. Lack of a full registry-based design may introduce selection bias, limiting generalisability. Lack of a full registry-based design may introduce selection bias, limiting generalisability. Introduction Retroperitoneal sarcomas (RPS) represent a rare category of malignant neoplasms with an annual incidence of 2.7 per 1 000 000.1 Histologically, these tumours predominantly include liposarcomas and leiomyosarcomas, although other subtypes such as solitary fibrous tumours and malignant peripheral nerve sheath tumours may also occur in this anatomical location.2 The 5-year overall survival rate is around 60%.3 Surgical therapy is a key component in the curative treatment of RPS. Surgical standard treatment for RPS to obtain complete tumour resection is multivisceral resection using surrounding organs and structures to keep the sarcoma covered by layers of uninvolved tissue. This technique was agreed on by experts in the field a decade ago.4 Those standards were accomplished after analysing large cohorts of RPS patients having undergone more extensive versus shelling-out procedures and demonstrating superiority of the more radical procedure in terms of recurrence rates and long-term survival. Thus, RPS surgeries are complex procedures, requiring removal of organs and structures neighbouring the sarcoma and therefore are accompanied by major complication rates of 16%–28% after surgical treatment even in experienced centres.57 Complication rates include septic episodes, anastomotic insufficiencies, bleeding and intrabdominal fistula formation. Both technical feasibility and the shared decision-making process with the patient are of fundamental importance for therapy planning and compliance. Whether there is an optimal multimodal treatment for RPS beyond radical resection remains unclear due to discordant results from the STRASS I (EORTC-62092) and STREXIT studies regarding the role of preoperative radiation. Adjuvant therapy after radical removal of RPS does not represent treatment recommended by guidelines.8 Postoperative radiation of the retroperitoneum and post-surgery remaining structures is challenging due to the loss of the spacer effect after tumour removal and anatomical shifts of adjacent structures into the radiation field.9 Adjuvant chemotherapy has been in use in trials very rarely and may be considered for high-grade RPS on an individual basis only.10 11 Regardless of any perioperative treatment, multivisceral resection of the RPS is the mainstay of therapy. Extensive retrospective analyses have documented that more than half of the patients in cohort studies for RPS required colorectal resection as part of sarcoma surgery.3 5 In principle, for both right- and left-sided RPS, the options include primary anastomosis without a stoma, primary anastomosis with temporary protective ileostomy or the creation of a Hartmann’s situation.12 The primary advantage of stoma formation lies in its ability to significantly reduce faecal contamination of the extensive surgical site in the event of an anastomotic leak, thereby mitigating the risk of severe subsequent complications.13 The disadvantages of stoma formation include the presence of the stoma itself, the necessity for a subsequent reversal surgery and the potential for impaired renal function due to fluid loss from small bowel stomas, which could be particularly relevant when nephrectomy is performed concurrently.14 As we know from colorectal tumours, colorectal resections alone are associated with a complication rate of 20%–30%.15 16 Septic complications, anastomotic insufficiencies and intestinal obstructions are among the most adverse events. RPS patients often undergo extensive resections that affect additional organ systems. While septic complications have been extensively evaluated in large retrospective studies, surgical strategies for colorectal reconstruction in the context of retroperitoneal sarcoma resections remain inadequately defined. While prospective cohort studies in rectal cancer have investigated detailed analyses of, for example, the effects of early or late ileostomy reversal on adjuvant chemotherapy, in RPS, it is not even defined when a stoma is indicated or which factors influence colorectal procedures.17 A systematic review shows that colorectal resections and stoma formation have a significant impact on postoperative health-related quality of life (HRQoL) of patients with colorectal cancer.18 For patients with RPS, who often experience the involvement of multiple organ systems during extensive multivisceral resections, specific data on these aspects are sparse.19 Colorectal procedures are among the most common interventions in RPS patients, accounting for almost 60% of cases.5 We are aware that colorectal resections can be associated with severe postoperative complications and influence HRQoL.20 In contrast to colorectal carcinoma surgery, we lack data for sarcoma resections. The rate of anastomotic insufficiencies per anastomosis remains undetermined. Additionally, data regarding stoma prevalence have not been published. The Colorectal Resections and Postoperative Quality of Life in Retroperitoneal Sarcoma Patients Across German-Speaking Sarcoma Centres (COLOSARC-Q) study is designed to explore surgical procedures, bowel surgery-related complications and HRQoL in patients undergoing colorectal procedures in the context of multivisceral resections for RPS. COLOSARC-Q has the potential to enhance preoperative shared decision-making and intraoperative strategies for colorectal resections in multivisceral procedures, with the aim of reducing complication rates and developing surgical approaches tailored to the specific needs of patients. Material and methods Study design COLOSARC-Q is a non-interventional, multicentre study conducted at sarcoma centres in Germany and Switzerland, initiated by the Sarcoma Centre Mannheim, Heidelberg University, Mannheim, Germany, financially supported by the German Sarcoma Foundation, and supported by the Association of Surgical Oncology of the German Society for General and Visceral Surgery. Following the study initiation, patient recruitment commenced on 27 January 2025 at the Sarcoma Centre Mannheim. A collaboration with 15 sarcoma centres in Germany and Switzerland is planned. In 2018, certification as a ‘sarcoma referral centre’ according to Deutsche Krebsgesellschaft (DKG) criteria was established in Germany. Certified sarcoma centres must comply with minimum quantities and standards; sarcoma resections must be performed by certified surgeons with annual and lifetime experience.21 Major analyses show significant advantages for sarcoma resection in a referral centre in terms of recurrence rate and survival.22 For this reason, COLOSARC-Q only involves centres that meet the quality criteria for the certification of sarcoma referral centres. The cooperation agreements are currently being finalised. COLOSARC-Q is designed for a duration of approximately 24 months. Excluding the preparation and evaluation phases, each lasting approximately 6 months, about 12 months are allocated for recruitment, data collection, quality-of-life assessments and the conduct of interviews. Patient enrolment commenced on 27 January 2025. The study is anticipated to reach completion in July 2026. Ethical approval and trial registration Ethical approval was granted by the Ethics Committee II of the University of Heidelberg (approval number 2024-562; 13 June 2024). The data protection review was approved by the data protection officer of the University of Heidelberg. Participation of other centres in the study requires local ethical approval. All patients will be required to sign an informed consent form. The study will be conducted in accordance with the current version of the Declaration of Helsinki and the International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) E6 guidelines. COLOSARC-Q is registered at ClinicalTrials.gov (NCT06943612) and in the German Clinical Trials Register (DRKS00034135). Patient involvement Patients were actively involved in the planning and implementation of COLOSARC-Q. In the study, patient representatives from the German Sarcoma Foundation and ILCO Baden-Württemberg, the patient advocacy group for stoma patients, played an integral role in designing and planning the quality-of-life assessment. Their contributions were especially valued in the development of the interview guide, ensuring that the study effectively addressed the relevant concerns and lived experiences of the patients. Inclusion criteria Eligible for inclusion in the study are patients who have a primary retroperitoneal sarcoma and who have undergone surgery at a DKG-certified sarcoma centre or a hospital meeting equivalent certification criteria. The DKG certification criteria include a preoperative presentation of all sarcoma patients in an interdisciplinary sarcoma board, a lifetime experience of the sarcoma surgeon with at least 50 sarcoma resections, including at least 25 visceral/RPS, and additionally, an annual performance of at least 10 visceral/retroperitoneal sarcoma surgeries. The inclusion criteria for COLOSARC-Q are as follows: histological confirmation of a primary retroperitoneal sarcoma, prior tumour resection including colorectal resection, surgery performed at a DKG-certified sarcoma centre or an equivalent hospital, and age of 18 years or older, in addition to providing written informed consent. The exclusion criterion is the absence of informed consent. Primary and secondary endpoints The primary endpoint of this study is the evaluation of colon and rectum resection and reconstruction techniques within the context of multivisceral resections for RPS. The primary objective is to assess the frequency of primary anastomosis compared with primary stoma formation during the resection of retroperitoneal sarcomas on the right versus the left side, as well as to characterise the surgical techniques employed for stoma creation (eg, hand-sewn or stapled). This involves a detailed collection and analysis of the surgical procedures, a documentation of the postoperative courses and complications encountered, with consideration of intraoperative and postoperative variables, patient- and tumour-specific factors, and their potential impact on outcomes. All variables are centrally collected and analysed to systematically identify patterns and differences across patients and procedures. Secondary endpoints focus on the postoperative complications associated with bowel resection and reconstruction during and following multivisceral resections for RPS. The study will determine the rate of anastomotic leakage and intra-abdominal septic complications, the incidence of secondary stoma creation, and the proportion of stomas that are subsequently reversed during a secondary operation. We will use the Comprehensive Complication Index (CCI), with a follow-up period up to 90 days postoperatively.23 The study will explore the influence of various patient, tumour and treatment-related factors on both primary and secondary outcomes. These include demographic parameters such as sex, age and body mass index, clinical factors like preoperative malnutrition (assessed via serum albumin levels) and comorbidities such as diabetes mellitus and coronary artery disease. Tumour characteristics, including size, laterality (left/right), histological subtype and grade, will also be considered. Additionally, the influence of neoadjuvant therapies (eg, radiotherapy, chemotherapy) on outcomes will be investigated. Intraoperative variables, such as operative duration, blood loss and the extent of surgical intervention (measured by the Weighted Organ Score of the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)), will be analysed for their potential influence on postoperative outcomes. The study further aims to assess HRQoL and changes in bowel function following colorectal resections as part of RPS treatment. Patient-reported outcomes will be collected using standardised questionnaires and semi-structured interviews. In addition, the study seeks to identify the specific challenges and needs of RPS patients who have undergone colorectal resection and reconstruction. This includes exploring issues related to patient education, home care, bowel function, stoma management, rehabilitation and the intensity and sequencing of postoperative therapies. By identifying these factors, the study has the potential to enhance the overall care and support provided to this patient population, ultimately improving their quality of life and long-term outcomes. Sample size calculation For RPS, 400–600 cases are reported annually in Germany.24 Of these, over 200 patients are treated at sarcoma referral centres, and an estimated 100 patients undergo surgery involving colorectal procedures. It remains unclear whether septic complications and stoma creation occur as frequently as in colorectal cancer. Developing a specific statistical plan is challenging, and the sample size calculation is rather pragmatic. The targeted sample size is designed to include as many high-quality centres as possible, with patients being included prospectively and retrospectively from a period of 2–3 years to assess current practice. For clinical and surgical data collection, at least 120 patients are to be included, with at least 40 patients each having left-sided and right-sided sarcomas. All patients (n=120) will then, on obtaining consent, be invited to participate in a written quality-of-life survey using validated questionnaires. We expect a response rate of at least 40%, corresponding to approximately 50 completed questionnaires. The semi-structured interviews will be conducted monocentrically in Mannheim with a cohort of at least 10–15 participants. This sample size is based on the expectation that thematic saturation will be achieved with this number of participants, meaning that further interviews would yield few or no new issues.25 Study workflow The study workflow involves the inclusion of patients from 10 to 15 sarcoma centres, with each centre enrolling patients locally. After obtaining written informed consent, clinical-surgical data are collected in the electronic Case Report Form (eCRF) by the enrolling centre. Simultaneously, quality-of-life data is gathered using standardised questionnaires. Patients complete the questionnaires either digitally at the centre, in paper format or send the completed forms by mail to the Sarcoma Centre Mannheim. Additionally, semi-structured interviews will be conducted in Mannheim with a selected cohort (n=10–15). Finally, all data will be centrally analysed in Mannheim, with the results subsequently presented and published. On completion of the study, all data will be archived in compliance with legal requirements. The entire workflow is depicted in figure 1. Study workflow. RPS, retroperitoneal sarcomas. Electronic Case Report Form Clinical-surgical data collection is conducted digitally through an eCRF, which is securely accessible to all participating centres via the Research Electronic Data Capture platform. The eCRF collects clinical and surgical data across the following categories: demographic data, nutritional status, medical history, laboratory values, tumour characteristics, imaging, oncological treatment, surgery (including organ and vessel resections and drains), bowel-specific aspects of surgery with detailed explanations on resection, anastomosis and stoma (if applicable), bleeding management, surgical complications, stoma-related complications (if applicable) and postoperative course of care and further treatments. The eCRF includes a maximum of 202 items, with not all questions relevant to every patient. As part of the eCRF, the weighted organ score of the TARPSWG5 and the Surgical Complexity Score26 are recorded. Surgical complications are further assessed using the Clavien-Dindo classification and interpreted according to the CCI.23 HRQoL assessment The HRQoL assessment is conducted using standardised questionnaires for all patients (n=120) and semi-structured interviews at the Sarcoma centre Mannheim (n=10–15). Questionnaires For the HRQoL assessment, patients will be provided with the standardised questionnaires QLQ-C3027 (version 3.0) and QLQ-CR2928 (version 3.0) by the European Organization forResearch and Treatment of Cancer (EORTC). While the EORTC QLQ-C30 questionnaire provides a broad assessment of HRQoL across various domains, such as physical functioning, emotional well-being and social interactions, the EORTC QLQ-CR29 specifically focuses on gastrointestinal symptoms. It addresses bowel function with separate questions for patients with and without a stoma. Patients will complete the questionnaires independently, without interaction with healthcare providers or study personnel, and with sufficient time to respond. Completion of the questionnaires is voluntary. The questionnaires consist of various functional and symptom scales and individual items. Scoring is performed according to a standardised scoring system. First, the raw score is calculated, followed by a linear transformation to standardise the raw score, resulting in values ranging from 0 to 100. These standardised values serve as the basis for the interpretation of the functional level. Semi-structured Interviews The interview guide for COLOSARC-Q was developed in collaboration with the Sarcoma Centre, the Department of Surgery and the Department of Oncology at the University Medical Centre Mannheim, in partnership with the Psycho-oncology Service Mannheim (in cooperation with the Central Institute for Mental Health). Additionally, input was provided by the Stoma Therapy and the Nutrition Outpatient Clinic at the University Medical Centre Mannheim. The draft of the interview guide was reviewed by several patient representatives from the German Sarcoma Foundation and ILCO Baden-Württemberg. The complete interview guide can be found in the online supplemental material. The semi-structured interviews for COLOSARC-Q are designed to address four key areas: physical functioning, bowel function and stoma, social environment and psychological factors (figure 2). Key themes of the semi-structured interviews. The interviews are conducted by physicians from the Sarcoma Centre Mannheim, accompanied by psycho-oncologists, and are designed to last approximately 60 min. The conversations are audio-recorded, followed by MAXQDA software-assisted transcription and analysis. The evaluation will involve a qualitative analysis, with data structured using content and context analysis to summarise the findings. Statistical analysis Descriptive statistical analyses are planned, and, where applicable, significance tests and group comparisons will also be performed. Continuous variables will be described by sample size, mean, median, SD, as well as the minimum and maximum values. Discrete variables will be presented as frequencies and percentages. Outcome variables will be analysed using both parametric and non-parametric methods, depending on their scale and distribution. Discussion The primary aim of COLOSARC-Q is the evaluation of colon and rectum resection and reconstruction techniques within the context of multivisceral resections for RPS. The objective is to assess the efficacy and safety of various surgical approaches employed in these complex cases, with a focus on optimising surgical outcomes. Multi-institutional cohort studies such as the comprehensive analyses of the TARPSWG describe the outcome of multivisceral resections for RPS and how frequent colorectal resections are performed in RPS surgery.5 20 Nevertheless, little is known about the exact number of anastomoses, anastomotic leakages (per anastomoses) and the fraction of patients with ileostomies or colostomies. We therefore initiated COLOSARC-Q to improve multimodal and surgical treatment allocation and shared decision-making. In the context of colorectal cancer surgery, septic complications and stoma formation occur in up to 30% of all cases.29 Patient (eg, age, malnutrition), treatment (eg, neoadjuvant radiation) and intraoperative factors (eg, blood loss) are known to influence the rates of anastomotic insufficiency, septic complications and perioperative mortality.30 It remains uncertain whether these factors are applicable to RPS surgery or whether additional factors, such as impaired renal function following nephrectomy or the inherent complexity of multivisceral resections, can be identified. These factors should potentially be incorporated into shared decision-making processes for colorectal resections within the context of multivisceral resections, particularly when considering the use of a temporary stoma. A stoma can help prevent severe complications, but may also be necessary as a result of such complications. A large retrospective analysis of over 1000 patients following RPS resections showed that anastomotic insufficiency, occurring in nearly 3% of cases, was one of the most common surgical complications.3 However, the number of leakages per anastomosis and the criteria for stoma placement in the context of RPS surgery have not been established. The data collection in COLOSARC-Q is based on the core dataset of the international registry study REtroperitoneal SArcoma Registry (RESAR) for RPS of the TRAPSWG. The registry study creates a broad data foundation for therapy and prognosis of RPS.31 COLOSARC-Q offers the opportunity to focus on therapy- and bowel-specific aspects in a smaller and more narrowly defined cohort. The design enables a cohort comparison between the TRAPSWG and COLOSARC-Q cohorts regarding epidemiological characteristics, serving as a tool for quality assurance. As the study does not follow a full registry-based design, there may be inherent biases in cohort selection, which could limit the generalisability of the findings. HRQoL of more than 1000 German sarcoma patients has been investigated in the multicentre observational PROSA (Patient-Reported Outcome measures in Sarcoma) study.32 In the subgroup analysis of patients with RPS from the PROSA study, gastrointestinal symptoms such as appetite loss, diarrhoea and constipation were among the top 10 most common symptoms, alongside dyspnoea, fatigue and pain.19 A sophisticated comparison of RPS patients with versus without colorectal procedures with patients after surgery for colorectal cancer has never been performed. Patients with rectal cancer exhibit digestive problems as well as emotional and social complaints, including depression, which represent a considerable postoperative burden.33 It is unknown if and to what extent RPS patients develop similar symptoms after surgery involving the colon and rectum. COLOSARC-Q offers the opportunity to examine these symptoms in greater detail. We will use established and validated EORTC QLQ-C30 and QLQ-CR29 quality-of-life questionnaires addressing HRQoL in general and gastrointestinal issues. Since standard questionnaires may not be comprehensive enough to describe the HRQoL of RPS patients, we will use semi-structured interviews in addition. Semi-structured interviews are an established method for capturing HRQoL and patients’ needs. The interviews are based on a guide that provides a thematic framework for the conversation.34 The advantage of this interview method is that not all questions in the guide need to be addressed; rather, the conversation can be adapted to the individual experiences of the patients.35 This interview format is selected for COLOSARC-Q because it enables an exploration of additional topics that supplement the questionnaires. The knowledge of specific patient needs within the framework of perioperative planning forms the basis for promoting shared decision-making. Particularly in the context of patient interviews, the aim is to gather patients’ needs through personal exchanges between patients and experts, to adapt and improve perioperative processes, such as surgical counselling, planning of postoperative home care and complication management. For this reason, patient advocates and representatives are involved in the design of the semi-structured interviews and general planning of the COLOSARC-Q study. Multimodal and surgical treatment of RPS is challenging and associated with high morbidity for patients. Decisions on surgical strategies, including colorectal procedures, most probably impact the risk and consequences of postoperative complications. Shared decision-making should therefore take into account all relevant aspects of RPS therapy, including HRQoL after RPS surgery. COLOSARC-Q provides an opportunity to expand our understanding of colorectal procedures in RPS surgery, potentially leading to better outcomes, reduced complication rates and enhanced shared decision-making in RPS treatment. Conclusion In conclusion, the COLOSARC-Q project seeks to generate essential insights into colorectal resections within the context of multivisceral resections for RPS. The primary focus will be on providing valuable surgical evidence and addressing the management of postoperative complications regarding colorectal procedures, while also assessing HRQoL and patients’ needs. COLOSARC-Q has the potential to enhance shared decision-making and intraoperative strategies for colorectal resections in RPS surgery, with the primary aim of reducing complication rates and developing personalised surgical approaches tailored to individual patient requirements. Ethics and dissemination Ethical approval was granted by the Ethics Committee II of the University of Heidelberg (approval number 2024-562; 13 June 2024). The data protection review was approved by the data protection officer of the University of Heidelberg. Participation of other centres in the study requires local ethical approval. All patients will be required to sign an informed consent form. Results of primary and secondary endpoints will be published in scientific journals and disseminated in a comprehensible format to the general public through the German Sarcoma Foundation. Supplementary material